Niangmei Cheng

The United Innovation Of Mengchao Hepatobiliary Technology Key Laboratory Of Fujian Province, 66 Jintang Road
Fuzhou, 350025, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

LncRNA MKRN3-AS1 promotes metastasis and autophagy of hepatocellular carcinoma by sponging multiple microRNAs.

LncRNA MKRN3-AS1 promotes metastasis and autophagy of hepatocellular carcinoma by sponging multiple microRNAs.

Journal: Scientific reports

Published: May 03, 2026

p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling.

p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling.

Journal: Molecular and cellular biochemistry

Published: February 13, 2026

Correction: Targeted Inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications.

Correction: Targeted Inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 25, 2025

Utilization of artificial circular RNAs as miRNA sponges and anti-PD-1 scFv expression platforms to suppress hepatocellular carcinoma progression.

Utilization of artificial circular RNAs as miRNA sponges and anti-PD-1 scFv expression platforms to suppress hepatocellular carcinoma progression.

Journal: Frontiers in immunology

Published: April 10, 2025

Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications.

Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 26, 2025

Hypoxia induces hepatocellular carcinoma metastasis via the HIF-1α/METTL16/lnc-CSMD1-7/RBFOX2 axis.

Hypoxia induces hepatocellular carcinoma metastasis via the HIF-1α/METTL16/lnc-CSMD1-7/RBFOX2 axis.

Journal: iScience

Published: June 27, 2023

LncRNA TIALD contributes to hepatocellular carcinoma metastasis via inducing AURKA lysosomal degradation.

LncRNA TIALD contributes to hepatocellular carcinoma metastasis via inducing AURKA lysosomal degradation.

Journal: Cell death discovery

Published: May 25, 2023

Lnc-PLA2G4A-4 facilitates the progression of hepatocellular carcinoma by inducing versican expression via sponging miR-23b-3p.

Lnc-PLA2G4A-4 facilitates the progression of hepatocellular carcinoma by inducing versican expression via sponging miR-23b-3p.

Journal: Heliyon

Published: April 25, 2023

Lnc-CCNH-8 promotes immune escape by up-regulating PD-L1 in hepatocellular carcinoma.

Lnc-CCNH-8 promotes immune escape by up-regulating PD-L1 in hepatocellular carcinoma.

Journal: Molecular therapy. Nucleic acids

Published: April 22, 2023

Hsa_circ_0001687 Function as a ceRNA to Facilitate Hepatocellular Carcinoma Progression via miR-140- 3p/FOXQ1 Axis.

Hsa_circ_0001687 Function as a ceRNA to Facilitate Hepatocellular Carcinoma Progression via miR-140- 3p/FOXQ1 Axis.

Journal: Protein and peptide letters

Published: November 23, 2022

Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression.

Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression.

Journal: Drug delivery and translational research

Published: September 03, 2022

Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.

Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.

Journal: World journal of surgical oncology

Published: September 30, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026